MedTrace Logo

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

NCT02860897 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-05-02

No results posted yet for this study

Summary

PURPOSE: To evaluate patient adherence to cream versus tablet based local estrogen therapy by randomizing treatment modalities to determine differences in adherence to either form.

HYPOTHESIS: There is no difference in adherence to cream versus tablet based local estrogen therapy when prescribed as a 6 week course of postoperative therapy after female pelvic reconstructive surgery.

Conditions

  • Estrogen
  • Menopause
  • Pelvic Floor Disorders
  • Surgery

Interventions

DRUG

Premarin

Vaginal estrogen cream

DRUG

Vagifem

Vaginal estrogen tablet

Sponsors & Collaborators

  • University Hospitals Cleveland Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-04-30
Completion
2017-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860897 on ClinicalTrials.gov